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Abstract Indomethacin, a common non-steroidal anti-inflam- 
matory drug (NSAID), has been used to treat rheumatoid arthri- 
tis. Although indomethacin has also been used as an immunopo- 
tentiator and symptomatic NSAID in AIDS, its effect on HIV 
replication is unknown. MT-4 lymphocytes were inoculated with 
HIV in the presence of indomethacin and tested for p24 expres- 
sion by ELISA. The 50% inhibition (IC5o) was 10 ~M, corre- 
sponding to plasma levels after administration of 50 mg oral 
indomethacin. The antiviral effect appears to be specific since no 
toxicity has been observed at the ICs0 dose, and unrelated 
NSAIDs have not shown the activity at clinical doses. Indometh- 
acin may, thus, represent a new class of anti-HIV drug. 
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conditions. The exact mechanism of anti-inflammatory, analge- 
sic, and antipyretic action of indomethacin is not known, al- 
though it has been commonly associated with interference of 
fatty acid metabolism, i.e. inhibition of prostaglandin synthesis 
by blocking cyclooxygenase (CO) activity. 
Indomethacin has been proposed and subsequently used, 
albeit with mixed results, for the improvement of the immune 
function of HIV-positive patients [3 5]. However, to the best 
of our knowledge, there are no published reports investigating 
the direct effect of indomethacin on HIV replication. In this 
study we have examined this particular indole derivative for its 
capacity to prevent de novo HIV infection, and compared it to 
other structurally related and unrelated NSAIDs in a standard 
antiviral assay based on measurement of p24 production. 
2. Materials and methods 
I. Introduction 
After fifteen years of the AIDS epidemic no effective anti- 
HIV therapy has been developed. This is partly due to the fact 
that the focus of research has been concentrated on a limited 
number of viral targets, e.g. reverse transcriptase and HIV 
protease. Despite an enormous wealth of accumulated knowl- 
edge about HIV and its relationship with host cells, so far, this 
information has not been translated into meaningful therapy. 
However, it is clear that an antiviral strategy needs to be diver- 
sified by investigating compounds aimed at cellular targets. 
In the past we have investigated several drugs affecting pri- 
marily cellular functions [1] and found that they were acting as 
HIV inhibitors at pharmacologically relevant concentrations 
without exhibiting the cytotoxicity usually associated with ad- 
ministration of anti-HIV drugs like AZT. These compounds, 
e.g. estrogen, progesterone, chorionic gonadotropin, coumar- 
ins, warfarin, bestatin, levamisole, various plant-derived pro- 
teins, etc., were already used in clinics for unrelated therapeutic 
purposes. 
Indomethacin is a non-steroidal anti-inflammatory drug 
(NSAID) with multiple effects on immune function [2]. This 
compound is among the drugs of choice for relieving pain and 
fever. For more than thirty years indomethacin has been used 
for symptomatic treatment of rheumatoid arthritis and related 
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Abbreviations: AIDS, acquired immunodeficiency s ndrome; CH, 
cholesterol; CO, cyclooxygenase; HIV, human immunodeficiency virus; 
LP, 5-1ipoxygenase; NGDA, nordihydroguaiaretic acid; PG, prosta- 
glandin; PL, phospholipid. 
2.1. Drugs 
Various antagonists of CO, including indomethacin, indoprofen, 
naproxen, ibuprofen, acetylsalicylic acid (aspirin), and 5-1ipoxygenase 
(LP) inhibitor, nordihydroguaiaretic acid (NDGA), were purchased 
from Sigma (St. Louis, MO), stored at 4°C as stock 100 mM solutions 
in appropriate solvents and used thereafter. 
2.2. Virus 
Virus inoculum was derived from 0.22/tm-filtered supernatant of 
H9/IIIB lymphocytes and stored frozen at -70°C as a stock solution 
at 100 ng p24 per ml. The number of HIV particles in culture superna- 
tant was determined by p24 ELISA and infectious viral titer was deter- 
mined by limiting end-point dilution assay [6]. 
2.3. Antiviral assay 
The CD4+ T cell line MT-4 was used as the indicator cell for the p24 
expression assay. Commercial p24 ELISA kits were purchased from 
Coulter (Hialeah, FL). All antiviral assays were carried out in 96-well 
culture plates with each well containing 2 x 104 MT-4 cells in 200 pl 
RPMI 1640 medium with 10% FCS. Serial ten-fold dilutions of test 
drugs were added and followed by addition of the virus. The final 
concentration of the viral inoculum in microwell cells was equivalent 
to 100 infectious units per lymphocyte. The mixture of cells, virus, and 
drugs was left for 2 days until tested for p24. The values of p24 corre- 
sponding to original viral inoculum left in wells without MT-4 were 
used as blanks, in order to discriminate newly synthesized virus from 
residual virus inoculum. Each drug was tested at least three times in 
triplicate wells. 
2.4. Cytotoxieity assay 
The toxicity of NSAIDs was determined by colorimetric assay of the 
viability of MT-4 cells. The assay is based on measuring the conversion 
of XTT tetrazolium salt by mitochondrial hydrogenases into a color 
dense formazan product [7]. The culture conditions, culture plates and 
initial cell number of MT-4 were the same as in the antiviral assay. 
Serial log concentrations of NSAIDs were added to MT-4, incubated 
for 2 days, and XTT (1 mg/ml) was added for 3 h. The optical density 
was then measured in a plate reader (SLT Spectra, Salzburg, Austria) 
at a wavelength of 450 nm with the reference filter at 620 nm. 
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Fig. 1. The effect of various NSAIDs on HIV infection as measured by p24 ELISA of MT-4 culture supernatant on day 2. Effect of NSAIDs on 
MT-4 viability following 2 days of continuous exposure as measured by XTT assay is shown as percent of controls on the left ordinate. Naproxen, 
indoprofen, and ibuprofen were effective but at a 1 mM cytotoxic dose. Aspirin had no significant effect even at the highest tested ose. Indomethacin 
and the experimental lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), were able to suppress HIV replication without aconcurring negative 
effect on cell viability. 
3. Results 
At two days post-infection, virus-inoculated MT-4 cells 
started to display signs of cytopathic effect, i.e. syncytia forma- 
tion. The number of syncytial cells appeared to correlate in- 
versely with the concentration of indomethacin present in 
treated wells. This phenomenon was not observed in wells 
treated with equimolar concentrations of other NSAIDs. In- 
stead of relying on counting syncytial cells - a biased and 
obsolete assay - the effect was quantitated by measuring the 
levels of p24 antigen by ELISA. The results are summarized in
Fig. 1. The 50% inhibitory concentration (ICs0) was equivalent 
to l0 ~tM of indomethacin a d was determined on the basis of 
three separate xperiments with three replicate wells. Other CO 
inhibitors, i.e. aspirin, indoprofen, ibuprofen, and naproxen, 
have not shown any appreciable activity at concentrations that 
were not associated with concurring cytotoxicity. The least 
toxic drug, aspirin, was the least effective against HIV. In con- 
trast, the LP inhibitor, nordihydroguaiaretic acid, has demon- 
strated an anti-HIV effect at a non-toxic concentration of
10//M. 
Although some NSAIDs appeared to be cytolytic at effective 
concentrations, indomethacin was not toxic since the morphol- 
ogy of treated cells was indistinguishable from untreated con- 
trols. This was confirmed by cell viability XTT tests (Fig. 1). 
4. Discussion 
In this study we have evaluated the effect of select inhibitors 
of cyclooxygenase and lipoxygenase. De novo HIV infection 
was suppressed in a dose-dependent fashion by a CO antago- 
nist, indomethacin. Nordihydroguaiaretic acid, although less 
selective, has also shown antiviral activity at non-toxic oncen- 
trations. The structurally related and unrelated NSAIDs such 
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as indoprofen, aspirin, ibuprofen, and naproxen, recognized as 
equally potent inhibitors of prostaglandin (PG) synthesis, were 
not effective in the pharmacological non-toxic dosage range. 
This suggests that the anti-HIV effect is determined by a unique 
property of indomethacin and agrees with the opinion that the 
cellular action of indomethacin does not necessarily involve PG 
inhibition [8]. The anti-HIV role of PGs themselves has been 
controversial; while one group claimed that PGs were enhanc- 
ing the replication of HIV [9], others reported the opposite 
effect [10-12]. 
Little is known about how viral infection can be prevented 
by suppressing the function of CO and LP as precursors of 
prostaglandins and leukotrienes. Schroder et al. [13] have asso- 
ciated the effect of sesquiterpenoid hydroquinone, an experi- 
mental HIV inhibitor, with reduced levels of eucosanoids via 
inhibition of both CO and LP. Other investigators who have 
observed the suppressive ffect of indomethacin on various 
types of viruses have indicated that the effect could not be 
attributed to inhibition of PG [14~17]. Furthermore, indometh- 
acin was occasionally shown either to have no effect [18] or to 
enhance virus yields and pathogenic effects in the host [19,20]. 
Thus, despite the unusual broad-spectrum activity of indometh- 
acin interfering with replication of many types of viruses, the 
mechanism remains unclear. 
Some researchers have turned their attention to indirect ex- 
planations uch as an enhancement of cellular immune re- 
sponse to viruses [21]. Others attributed its effect to modifica- 
tion of lipid composition and fluidity of the cell membrane, 
implicated in both the regulation of immune function and virus 
infection [22]. Several studies have demonstrated a correlation 
between the infectious capacity of HIV in vitro and alterations 
in the plasma membrane lipid composition [23 29]. Phosphol- 
ipids (PL) and cholesterol (CH) are important components of 
cell membrane fluidity, prostaglandin.and leukotriene synthe- 
sis, and cellular metabolic processes uch as inflammatory 
processes, carcinogenesis, and viral infection. Lipid profile al- 
terations leading to increased concentration of membrane CH 
and/or polyunsaturated lipids causes a decrease in membrane 
fluidity. The CH/PL ratio is two times higher in HIV-infected 
than in uninfected cells. The evidence from clinical observa- 
tions also indicates that patients with AIDS exhibit marked 
disturbances in lipid, lipoprotein, and triglyceride metabolism 
[30]. The relationship between HIV infection, changes in mem- 
brane fluidity and activation of phospholipase and the ara- 
chidonic acid cascade in lymphocytes has been well docu- 
mented [31,32]. The elevation in the levels of unsaturated fatty 
acids leads to an increase in cell membrane fluidity and has been 
associated with enhanced virus-cell fusion and syncytium for- 
mation [28,29]. Since indomethacin causes a decrease in mem- 
brane fluidity it is possible this mechanism is responsible for the 
observed effect in our study. In contrast, aspirin, shown to have 
an opposite ffect on the membrane status, is the least active 
drug in our assay [8,33]. 
Oral administration of 50 mg of indomethacin generates a 
peak plasma concentration f the drug ranging from 7 to 11/zM 
[2], a concentration which inhibits HIV replication in vitro. 
Indomethacin has already been used in clinics by HIV-infected 
individuals. While some groups have doubted that the benefit 
of indomethacin could be ascribed to anything more significant 
than simple relief from pain and fever [5], others claimed a 
beneficial immunopotentiating effect such as improved lym- 
phoproliferative r sponse and restoration of the CD4/CD8 
ratio [3,4]. Unfortunately, there are no studies aimed at estab- 
lishing its effect on the levels of viremia and it is unknown 
whether this drug may have an antiviral effect in vivo. 
The concept of manipulating lipid composition and fluidity 
of the viral or host cell membrane by inhibitors of CO and LP 
has already been utilized for targeted therapeutic nterventions 
[13,34]. The membrane perturbing amphiphile, indomethacin, 
represents a new class of molecules which may help to better 
understand the relationship between HIV and host cells and 
may serve as the lead compound for designing even more effec- 
tive anti-AIDS drugs. 
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